1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Viatris Scoops Another Preferred Formulary Listing For Interchangeable Semglee

Prime Therapeutics Decision For Insulin Glargine Biosimilar Follows Express Scripts

 
• By Dean Rudge

Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.

Pair of aces with poker chips
Prime Therapeutics has followed suit with Express Scripts • Source: Alamy

Prime Therapeutics, a pharmacy benefit manager which serves nearly 33 million people and is collectively owned by 19 Blue Cross and Blue Shield plans or affiliates, has followed action by fellow PBM Express Scripts and announced it will put Viatris/Biocon’s interchangeable insulin glargine products on its preferred national formulary.

Viatris’ recently approved Semglee (insulin glargine-yfgn) biosimilar, which is designated as interchangeable with Sanofi’s Lantus reference brand, will gain preferred status from 1 January 2022, alongside the firm’s authorized

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Aurobindo Racks Up Another Biosimilar Nod With Filgrastim In UK

 
• By Dave Wallace

Aurobindo’s run of biosimilar registration successes continues, with the firm’s CuraTeQ subsidiary picking up approval for its Zefylti version of filgrastim in the UK.

J&J Hits Back Over Private-Label Stelara Biosimilar In US

 
• By Dave Wallace

After being refused an injunction as part of ongoing litigation over a private-label ustekinumab biosimilar being marketed in the US by Sandoz and Samsung Bioepis, Stelara originator Johnson & Johnson is continuing to pursue an appeal. However, newly-unsealed court documents suggest the brand company had demonstrated a likelihood of success - and reveal further details about the case, including the identity of the PBM involved and why the injunction request was denied.

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

More from Products

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.